These findings imply NAD+ may be a potential novel therapeutic method in CCH-induced cognitive impairment, and targeting Sirt1/PGC-1α pathway may be a promising treatment strategy in VaD. This evidence concerns the gene PPARGC1A and Cognitive impairment.